To third dose Prior, 33% (n?= 11) of individuals with solid tumor and 40% (n?= 6) of individuals with hematological malignancies got detectable T?cell reactions.
To third dose Prior, 33% (n?= 11) of individuals with solid tumor and 40% (n?= 6) of individuals with hematological malignancies got detectable T?cell reactions.